Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top

Cancer and Metastasis Reviews

Issue 2/2005

Content (15 Articles)

Introduction

Meenhard Herlyn

Integrin signaling in malignant melanoma

Silke Kuphal, Richard Bauer, Anja-Katrin Bosserhoff

Activated leukocyte cell adhesion molecule (ALCAM/CD166): Signaling at the divide of melanoma cell clustering and cell migration?

Guido W. M. Swart, Pim C. Lunter, Jeroen W. J. van Kilsdonk, Leon C. L. T. van Kempen

A Wnt-er Wonderland—The complexity of Wnt signaling in melanoma

Ashani T. Weeraratna

Bone morphogenetic proteins in melanoma: Angel or devil?

Mei-Yu Hsu, Sherry Rovinsky, Sunita Penmatcha, Meenhard Herlyn, DesiRae Muirhead

SKI pathways inducing progression of human melanoma

Jon A. Reed, Qiushi Lin, Dahu Chen, I. Saira Mian, Estela E. Medrano

Functional and therapeutic significance of Akt deregulation in malignant melanoma

Gavin P. Robertson

Protein kinase C in melanoma

Masahiro Oka, Ushio Kikkawa

Role of nuclear factor-κ B in melanoma

Katayoun I. Amiri, Ann Richmond

Targeting STAT3 affects melanoma on multiple fronts

Marcin Kortylewski, Richard Jove, Hua Yu

De-regulation of ubiquitin-dependent proteolysis and the pathogenesis of malignant melanoma

Serge Y. Fuchs

Rb/E2F: A two-edged sword in the melanocytic system

Ruth Halaban

Immunological detection of altered signaling molecules involved in melanoma development

Yutaka Kawakami, Hidetoshi Sumimoto, Tomonobu Fujita, Yuriko Matsuzaki

Erratum, The role of B-RAF in melanoma

Vanessa C. Gray-Schopfer, Silvy da Rocha Dias, Richard Marais

Guest Editor

Meenhard Herlyn

Jan 05
Issue: 1/2005
Sep 05
Issue: 3/2005

Latest issues

scroll for more

use your arrow keys for more

scroll or use arrow keys for more

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits